We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Single Molecule Array Predicts Survival After Prostatectomy

By LabMedica International staff writers
Posted on 03 Nov 2011
A fifth-generation digital immunoassay is a reliable predictor of five-year biochemical recurrence (BCR)-free survival following radical prostatectomy (RP).

The immunoassay uses Single Molecule Array (SiMoA) technology based upon the isolation of individual immunocomplexes on beads using standard enzyme linked immunosorbent assay (ELISA) reagents. More...


Scientists utilized frozen serum specimens, provided by the Langone Medical Center (New York University, NY, USA), and the Johns Hopkins University School of Medicine (Baltimore, MD, USA), from men who had undergone RP and who had no evidence of BCR using conventional Prostate Specific Antigen (PSA) measurement methods.

The Quanterix AccuPSA assay (Quanterix Corporation, Cambridge, MA, USA), was capable of accurately measuring PSA levels in all men following surgery. The Quanterix assay has an analytical sensitivity 1,000-fold lower than conventional ultra sensitive PSA assays. AccuPSA nadir levels were significantly different between the non-BCR group whose mean was 2.27 pg/mL and the BCR group whose mean was 46.99 pg/mL. A Kaplan-Meir analysis demonstrated for the five years follow-up, 100% of men with AccuPSA nadir values of less than 3 pg/mL did not develop BCR, whereas 62.5% of men with values greater than 3 pg/mL developed BCR. The sensitivity, specificity, positive predictive value and negative predictive value of the AccuPSA test was 100%, 75%, 69% and 100% respectively.

Herbert Lepor, MD, a prostate cancer expert at NYU, said, "These results have important implications for the way prostatectomy patients will be managed in the future. Not only will physicians be able to reassure patients who are at low risk of recurrence following radical prostatectomy, but the identification of a reliable predictor of recurrence soon after surgery has important implications for the frequency of PSA testing and selection of candidates for adjuvant therapy. In addition to providing patients with peace of mind, implementation of this test could lead to a reduction in healthcare costs.” The study was published online on October 12, 2011, in the British Journal of Urology International.


Related Links:
New York University Langone Medical Center
Johns Hopkins University School of Medicine
Quanterix Corporation




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Pancreas cells (left) showing early stages of malignant cancer in brown and same cells stained blue (right) indicate they are Integrin β3 (ITGB3) positive (Photo courtesy of UC San Diego Health Sciences)

Gene Signature Could Serve as Early Warning System for Aggressive Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal forms of cancer, with early detection remaining a major challenge. Precancerous cells must overcome significant stress and... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.